London-based Latent Labs has launched what it calls a “frontier AI model” for protein binder design, claiming hit rates of 91-100% for macrocycles and 10-64% for mini-binders across seven therapeutic targets, a dramatic improvement over traditional drug discovery’s sub-1% success rates.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile